Day One Biopharmaceuticals Inc (DAWN)

$6.65 -0.06 (-0.89%)
Market Cap 674.06M
Revenue (ttm) 131.16M
Net Income (ttm) -95.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -72.81%
Debt to Equity Ratio 0.00
Volume 1,052,700
Avg Vol 1,302,210
Day's Range N/A - N/A
Shares Out 101.36M
Stochastic %K 23%
Beta -1.26
Analysts Strong Sell
Price Target $28.00

Company Profile

Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 484 0899
Address:
1800 Sierra Point Parkway, Suite 200, Brisbane, United States
mollielatham
mollielatham Aug. 3 at 1:21 AM
$DAWN 400 mil in cash--what can go wrong ?
0 · Reply
StockScanners
StockScanners Aug. 2 at 6:34 PM
$DAWN needs to hold above 6.20 , watch reversal
0 · Reply
St0ckt0k101
St0ckt0k101 Aug. 2 at 6:17 PM
$DAWN is trending hmm 🤨✅
0 · Reply
FesertBoy
FesertBoy Aug. 2 at 5:29 PM
$DAWN 26k shares
1 · Reply
FesertBoy
FesertBoy Aug. 2 at 5:28 PM
$DAWN in for 25k shares. Should easily be up over 8.5 or 9 after earnings… if not over
0 · Reply
toro7
toro7 Aug. 2 at 1:43 PM
$DAWN
0 · Reply
StockKilla77
StockKilla77 Aug. 2 at 3:47 AM
@BioCapitalist99 yo brother check out $DAWN when u can I think it’s similar to $NUVB lmk what u think
0 · Reply
Bioshortbig
Bioshortbig Aug. 1 at 3:23 PM
$DAWN absolutely Pos fraud company 💩👈🏻
1 · Reply
Bioshortbig
Bioshortbig Aug. 1 at 2:10 PM
$DAWN only Short...every DAY.... Ultra SCAM
0 · Reply
DiamondHandsBTW
DiamondHandsBTW Aug. 1 at 1:31 PM
$DAWN I’m just shocked there has been no insider buys at this level
0 · Reply
Latest News on DAWN
Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025

Jul 22, 2025, 8:30 AM EDT - 11 days ago

Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025

Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

Jun 10, 2025, 8:30 AM EDT - 7 weeks ago

Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301

Jun 4, 2025, 8:59 PM EDT - 2 months ago

Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301

Day One Biopharmaceuticals, Inc. (DAWN) Q1 2025 Earnings Call Transcript

May 6, 2025, 10:12 PM EDT - 3 months ago

Day One Biopharmaceuticals, Inc. (DAWN) Q1 2025 Earnings Call Transcript

Day One Reports First Quarter 2025 Financial Results and Corporate Progress

May 6, 2025, 4:01 PM EDT - 3 months ago

Day One Reports First Quarter 2025 Financial Results and Corporate Progress

Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

Apr 22, 2025, 8:30 AM EDT - 3 months ago

Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity

Apr 10, 2025, 11:51 PM EDT - 4 months ago

Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity

Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 7:02 AM EST - 5 months ago

Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call Transcript

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

Feb 25, 2025, 4:05 PM EST - 5 months ago

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

Feb 11, 2025, 8:30 AM EST - 6 months ago

Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)

Jan 7, 2025, 11:31 AM EST - 7 months ago

Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)

Day One Biopharmaceuticals: Sales Figures In The Crosshairs

Dec 25, 2024, 7:31 AM EST - 7 months ago

Day One Biopharmaceuticals: Sales Figures In The Crosshairs

Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 17, 2024, 8:30 AM EST - 8 months ago

Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

Nov 20, 2024, 4:30 PM EST - 9 months ago

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 18, 2024, 8:30 AM EST - 9 months ago

Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference

Day One Biopharmaceuticals, Inc. (DAWN) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 10:57 PM EDT - 9 months ago

Day One Biopharmaceuticals, Inc. (DAWN) Q3 2024 Earnings Call Transcript

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

Oct 30, 2024, 4:01 PM EDT - 9 months ago

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024

Oct 16, 2024, 8:30 AM EDT - 10 months ago

Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024

Day One Reports Second Quarter 2024 Financial Results and Corporate Progress

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Day One Reports Second Quarter 2024 Financial Results and Corporate Progress

Day One Announces Oversubscribed $175.0 Million Private Placement

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Day One Announces Oversubscribed $175.0 Million Private Placement

Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor

Jul 25, 2024, 12:58 AM EDT - 1 year ago

Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

Jun 18, 2024, 8:30 AM EDT - 1 year ago

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

Day One Announces Sale of Priority Review Voucher for $108 Million

May 30, 2024, 8:30 AM EDT - 1 year ago

Day One Announces Sale of Priority Review Voucher for $108 Million

Day One Reports First Quarter 2024 Financial Results and Corporate Progress

May 6, 2024, 4:30 PM EDT - 1 year ago

Day One Reports First Quarter 2024 Financial Results and Corporate Progress

Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

Apr 23, 2024, 3:56 PM EDT - 1 year ago

Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

Feb 26, 2024, 4:30 PM EST - 1 year ago

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects

Feb 1, 2024, 10:07 AM EST - 1 year ago

Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects

Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 19, 2023, 8:00 AM EST - 1 year ago

Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

Nov 17, 2023, 7:00 AM EST - 1 year ago

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

Day One Reports Third Quarter 2023 Financial Results and Corporate Progress

Nov 6, 2023, 4:30 PM EST - 1 year ago

Day One Reports Third Quarter 2023 Financial Results and Corporate Progress

Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Oct 30, 2023, 8:00 AM EDT - 1 year ago

Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Day One Biopharmaceuticals: NDA Filing Decision Is An Inflection Point To Watch

Sep 15, 2023, 3:21 PM EDT - 2 years ago

Day One Biopharmaceuticals: NDA Filing Decision Is An Inflection Point To Watch

Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Sep 11, 2023, 9:02 PM EDT - 2 years ago

Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Day One Reports Second Quarter 2023 Financial Results and Corporate Progress

Aug 7, 2023, 4:30 PM EDT - 2 years ago

Day One Reports Second Quarter 2023 Financial Results and Corporate Progress

Diving Into Day One Biopharmaceuticals

Jul 23, 2023, 4:43 AM EDT - 2 years ago

Diving Into Day One Biopharmaceuticals

Day One Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jun 12, 2023, 8:00 AM EDT - 2 years ago

Day One Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Day One Announces Pricing of Public Offering of Common Stock

Jun 6, 2023, 10:31 PM EDT - 2 years ago

Day One Announces Pricing of Public Offering of Common Stock

Day One Announces Proposed Public Offering of Common Stock

Jun 6, 2023, 4:01 PM EDT - 2 years ago

Day One Announces Proposed Public Offering of Common Stock

Cancer drugmakers rise as industry meet fuels investor interest

Jun 5, 2023, 10:59 AM EDT - 2 years ago

Cancer drugmakers rise as industry meet fuels investor interest

EVAX GTHX

Day One Biopharmaceuticals shares jump 23% on positive results for glioma treatment

Jun 5, 2023, 8:09 AM EDT - 2 years ago

Day One Biopharmaceuticals shares jump 23% on positive results for glioma treatment

Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma

Jun 4, 2023, 12:45 PM EDT - 2 years ago

Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma

Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference

May 30, 2023, 8:00 AM EDT - 2 years ago

Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference

CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2023, 8:30 PM EDT - 2 years ago

CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2023, 5:00 PM EDT - 2 years ago

Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Day One Reports First Quarter 2023 Financial Results and Corporate Progress

May 1, 2023, 9:00 AM EDT - 2 years ago

Day One Reports First Quarter 2023 Financial Results and Corporate Progress

Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 26, 2023, 9:31 AM EDT - 2 years ago

Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress

Apr 12, 2023, 8:00 AM EDT - 2 years ago

Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress

Day One Biopharmaceuticals: Strong Potential, Price Drop Opportunity, Some Concerns

Apr 7, 2023, 7:37 AM EDT - 2 years ago

Day One Biopharmaceuticals: Strong Potential, Price Drop Opportunity, Some Concerns

Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress

Mar 6, 2023, 4:30 PM EST - 2 years ago

Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress

Day One to Participate in the Cowen 43rd Annual Health Care Conference

Feb 27, 2023, 8:00 AM EST - 2 years ago

Day One to Participate in the Cowen 43rd Annual Health Care Conference

mollielatham
mollielatham Aug. 3 at 1:21 AM
$DAWN 400 mil in cash--what can go wrong ?
0 · Reply
StockScanners
StockScanners Aug. 2 at 6:34 PM
$DAWN needs to hold above 6.20 , watch reversal
0 · Reply
St0ckt0k101
St0ckt0k101 Aug. 2 at 6:17 PM
$DAWN is trending hmm 🤨✅
0 · Reply
FesertBoy
FesertBoy Aug. 2 at 5:29 PM
$DAWN 26k shares
1 · Reply
FesertBoy
FesertBoy Aug. 2 at 5:28 PM
$DAWN in for 25k shares. Should easily be up over 8.5 or 9 after earnings… if not over
0 · Reply
toro7
toro7 Aug. 2 at 1:43 PM
$DAWN
0 · Reply
StockKilla77
StockKilla77 Aug. 2 at 3:47 AM
@BioCapitalist99 yo brother check out $DAWN when u can I think it’s similar to $NUVB lmk what u think
0 · Reply
Bioshortbig
Bioshortbig Aug. 1 at 3:23 PM
$DAWN absolutely Pos fraud company 💩👈🏻
1 · Reply
Bioshortbig
Bioshortbig Aug. 1 at 2:10 PM
$DAWN only Short...every DAY.... Ultra SCAM
0 · Reply
DiamondHandsBTW
DiamondHandsBTW Aug. 1 at 1:31 PM
$DAWN I’m just shocked there has been no insider buys at this level
0 · Reply
Bioshortbig
Bioshortbig Aug. 1 at 10:42 AM
$DAWN Zero incoming fast
1 · Reply
StockKilla77
StockKilla77 Aug. 1 at 2:10 AM
$DAWN prob a $15 to 20 stock by end of the year with ease. This company is ready for explosion and checks all the boxes for me
0 · Reply
Bioshortbig
Bioshortbig Jul. 31 at 4:54 PM
$DAWN delisting incoming fast this year 😘.... criminal ultra Pos fraud company $XBI Short it
1 · Reply
LDT79
LDT79 Jul. 31 at 3:09 PM
$DAWN so much manipulation
0 · Reply
Bioshortbig
Bioshortbig Jul. 31 at 3:07 PM
$DAWN greatest Short of All Time.... P2 OFF LABEL SCAM
0 · Reply
Bioshortbig
Bioshortbig Jul. 31 at 2:18 PM
$DAWN Ultra SCAM... Short it heavy
0 · Reply
tackinis
tackinis Jul. 31 at 2:13 AM
After I posted two weeks ago $IOVA got up also $NVNI, Holding $TNYA, getting in $VADP now! also $DAWN and $SIGA Im getting long for Weekly swings , Good luck everyone.
0 · Reply
Bioshortbig
Bioshortbig Jul. 30 at 7:03 PM
$DAWN only short...every DAY to Zero 👍🏻👍🏻
1 · Reply
Bio_Invest101
Bio_Invest101 Jul. 30 at 1:12 PM
$SLDB $IRWD starts at 6-minute mark FDA commissioner talking... https://www.youtube.com/watch?v=95yIs1FbP60&t=419s $DAWN $NUVB
0 · Reply
Bioshortbig
Bioshortbig Jul. 30 at 12:25 PM
$DAWN
2 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Jul. 29 at 11:04 PM
$DAWN
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Jul. 29 at 2:39 AM
$DAWN $ 36
0 · Reply